Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families
Pediatric Dermatology · 2026
DOI: 10.1111/pde.70285 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Dermatology, 2026. Verfasst von Maria Gnarra Buethe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Rady Children's Hospital-Orange County, Orange, California, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Recent publications reporting increased cutaneous T‐cell lymphoma (CTCL) risk with dupilumab in atopic dermatitis (AD) have sparked debate, amplified by media coverage linking dupilumab to lymphoma. These concerns have reached pediatric populations, where we observe increasing parental hesitancy about initiating dupilumab for their children. This hesitancy is particularly acute given that dupilumab was only approved for infants aged 6 months and older in 2022—the first cohort now approaching 3–4 years of exposure. Parents understandably question the long‐term effects of decades of IL‐4/IL‐13 blockade initiated during critical immune development periods. The diagnostic overlap between AD and mycosis fungoides (the most common CTCL) complicates assessment. We examine evidence regarding dupilumab safety and CTCL risk specifically in pediatric patients, incorporating recently presented long‐term open‐label extension data, and provide recommendations for monitoring, distinguishing AD from CTCL, and counseling families navigating this complex topic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, Rady Children's Hospital-Orange County, Orange, California, USA.
- Department of Dermatology, University of California, Irvine, Irvine, California, USA.
- Department of Pediatrics, University of California, Irvine, Irvine, California, USA.
- Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital-San Diego, San Diego, California, USA.
- Department of Dermatology, University of California, San Diego, School of Medicine, La Jolla, California, USA.
- Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, California, USA.
ORCID-Profile: Maria Gnarra Buethe
Zitieren
APA
Buethe, M. G., Sy, T., & Eichenfield, L. F. (2026). Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families. Pediatric Dermatology. https://doi.org/10.1111/pde.70285
Vancouver
Buethe MG, Sy T, Eichenfield LF. Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families. Pediatric Dermatology. 2026. doi:10.1111/pde.70285
BibTeX
@article{Buethe2026,
author = {Buethe, Maria Gnarra and Sy, Tyler and Eichenfield, Lawrence F},
title = {Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families},
journal = {Pediatric Dermatology},
year = {2026},
doi = {10.1111/pde.70285}
}
EUVIMED